Litcius/Paper detail

Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

Véronique Dièras, Hyo S. Han, Bella Kaufman, Hans Wildiers, Michael Friedländer, Jean-Pierre Ayoub, Shannon L. Puhalla, Igor Bondarenko, Mario Campone, Erik Jakobsen, Mathilde Jalving, Cristina Oprean, Markéta Palácová, Yeon Hee Park, Yaroslav Shparyk, Eduardo Yáñez, Nikhil Khandelwal, Madan G. Kundu, Matthew W. Dudley, Christine K. Ratajczak, David Maag, Banu Arun

2020The Lancet Oncology321 citationsDOIOpen Access PDF

Topics & Concepts

VeliparibCarboplatinOncologyMedicinePlaceboBreast cancerInternal medicineBRCA mutationPaclitaxelCancerChemotherapyBiologyGeneticsAlternative medicinePoly ADP ribose polymeraseCisplatinPathologyGenePolymerasePARP inhibition in cancer therapyCancer Treatment and PharmacologyAdvanced Breast Cancer Therapies
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial | Litcius